RecruitingNCT07273344

A Study on How the Immune System Responds to Sepsis and Its Long-term Effects

A Systems Immunology Approach to Characterize the Immune Response in Sepsis and Its Long-term Complications


Sponsor

Radboud University Medical Center

Enrollment

400 participants

Start Date

Nov 3, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Sepsis occurs when an infection, caused by bacteria, a virus, or a fungus, enters the body and throws the immune system out of balance. Instead of protecting the body, the immune response may become too strong and start damaging healthy organs, or it may become too weak and fail to control the infection. Both situations can be life-threatening. Even people who survive sepsis may experience long-term health problems, such as new infections, heart and blood vessel diseases, or early death. This study aims to better understand how the immune system behaves during and after sepsis. We believe that there are different types of immune responses in sepsis, called immunotypes. We will identify these immunotypes by examining substances in the blood and changes in immune cells. We will then study which immunotypes help protect patients and which may cause short- or long-term harm. Understanding these immunotypes may make it possible in the future to quickly determine what type of immune response a patient with sepsis has. This could help doctors choose the best treatment for each individual patient. A total of 400 patients with sepsis from the intensive care unit will take part in this study. We will collect blood samples at several time points and gather information about their health. Participants will be followed from their intensive care admission until one year after they return home.


Eligibility

Min Age: 18 Years

Inclusion Criteria2

  • Adults (≥18years).
  • Sepsis 3 criteria: defined as having a suspected or documented infection accompanied by organ dysfunction, represented by a total Sequential Organ Failure Assessment (SOFA-2) score 2 or more for new admissions or as 2 or more point-increase of the total SOFA-2 score for hospitalized patients.

Exclusion Criteria7

  • Known chemotherapy-induced or long-term neutropenia.
  • Known CD4 counts <400 cells/µL.
  • History of primary immunodeficiency
  • Chronic intake of corticosteroids (defined as total daily dose equal or greater than 0.4 mg/kg of equivalent prednisone for more than the last 15 days).
  • Current use of biologics.
  • Solid organ transplant recipients.
  • Recipients of allogeneic bone marrow transplants.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERblood sampling

This study involves no interventions beyond scheduled blood collection.


Locations(1)

Radboud University Medical Center

Nijmegen, Gelderland, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07273344


Related Trials